- Home
- BCG vs SYRS Comparison
BCG vs SYRS Comparison
Compare BCG & SYRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCG
- SYRS
- Stock Information
- Founded
- BCG 2016
- SYRS 2011
- Country
- BCG United States
- SYRS United States
- Employees
- BCG N/A
- SYRS N/A
- Industry
- BCG
- SYRS Biotechnology: Pharmaceutical Preparations
- Sector
- BCG
- SYRS Health Care
- Exchange
- BCG Nasdaq
- SYRS Nasdaq
- Market Cap
- BCG 45.6M
- SYRS 7.1M
- IPO Year
- BCG N/A
- SYRS 2016
- Fundamental
- Price
- BCG $2.14
- SYRS $0.22
- Analyst Decision
- BCG
- SYRS Hold
- Analyst Count
- BCG 0
- SYRS 5
- Target Price
- BCG N/A
- SYRS $3.00
- AVG Volume (30 Days)
- BCG 67.1K
- SYRS 2.7M
- Earning Date
- BCG 11-14-2024
- SYRS 10-31-2024
- Dividend Yield
- BCG N/A
- SYRS N/A
- EPS Growth
- BCG N/A
- SYRS N/A
- EPS
- BCG N/A
- SYRS N/A
- Revenue
- BCG $161,721,000.00
- SYRS $386,000.00
- Revenue This Year
- BCG N/A
- SYRS N/A
- Revenue Next Year
- BCG N/A
- SYRS $1,011.11
- P/E Ratio
- BCG N/A
- SYRS N/A
- Revenue Growth
- BCG N/A
- SYRS N/A
- 52 Week Low
- BCG $1.85
- SYRS $0.18
- 52 Week High
- BCG $16.61
- SYRS $8.17
- Technical
- Relative Strength Index (RSI)
- BCG N/A
- SYRS 29.17
- Support Level
- BCG N/A
- SYRS $0.19
- Resistance Level
- BCG N/A
- SYRS $0.21
- Average True Range (ATR)
- BCG 0.00
- SYRS 0.02
- MACD
- BCG 0.00
- SYRS 0.07
- Stochastic Oscillator
- BCG 0.00
- SYRS 20.53
About BCG Binah Capital Group Inc. Common Stock
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
About SYRS Syros Pharmaceuticals Inc.
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.